We are pleased to announce the publication of the KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis, published today in the March issue of Supplement to Kidney International, with an Executive Summary in the main pages of the journal. Read the news release: kdigo.co/2024-ANCA-Vasculiti… Read the guideline in Kidney International: kdigo.co/2024-ANCA-Vasculiti… Visit the KDIGO ANCA Vasculitis Website: kdigo.co/ANCA-Vasculitis-Gui… Developed under the stewardship of Co-Chairs Brad Rovin, MD (US) and Jürgen Floege, MD (DE), this guideline is an update to the ANCA Vasculitis chapter of the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. "The ANCA Vasculitis Guideline includes significant updates aimed at enhancing clinical decision-making, integrating new treatments with established clinical practices," stated Dr. Floege. "We anticipate that the comprehensive research, clinical perspectives, and collaborative expertise reflected in this guideline will contribute to better outcomes for individuals grappling with this complex condition." "We are excited to release the KDIGO 2024 ANCA Vasculitis Guideline, which offers new guidance for managing the intricacies of ANCA vasculitis treatment, particularly with the emergence of innovative therapies," said Dr. Rovin. "We are better equipped than ever to tailor interventions, optimize patient care, and strive towards improved outcomes for people with ANCA-associated vasculitis." KDIGO thanks the Guideline Work Group for their dedication and expertise and the Evidence Review Team from Brown University School of Public Health for their comprehensive work on this guideline. #ANCA #vasculitis #AAV #glomerular